Shire Pharmaceuticals
 |
|
| Public limited company | |
| Traded as | : NASDAQ: SHPG NASDAQ-100 Component |
| Industry | Pharmaceuticals |
| Predecessor | Shire Pharmaceuticals Group Plc |
| Founded | 1986 |
| Headquarters | Registered Office: St Helier, Jersey Corporate HQ: Dublin, Ireland UK Operations: Basingstoke, England |
|
Key people
|
Susan Kilsby (Chairman) Flemming Ørnskov, MD (CEO) |
| Revenue | $6,416.7 million (2015) |
| $1,419.5 million (2015) | |
| $1,303.4 million (2015) | |
|
Number of employees
|
5,300 (2014) |
| Website | www.shire.com |
Shire Plc is a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products include Vyvanse, Lialda, and Adderall XR. Shire has its primary listing on the and is a constituent of the FTSE 100 Index. Shire has a secondary listing on NASDAQ.
Shire is a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. The company's products are available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
The original corporate headquarters was located in Basingstoke, Hampshire, England. Main offices are located in Dublin, Ireland, the United States in Cambridge, Massachusetts and Chicago, Illinois and in Zug, Switzerland. In addition, Shire owns a manufacturing site in Lexington, Massachusetts and building a new manufacturing facility in Dublin, Ireland. It announced in November 2013 that it would be further reducing its presence in the UK.
Shire was founded in 1986 in the UK by four entrepreneurs. These four entrepreneurs were Harry Stratford, Dennis Stephens, Peter Moriarty, and Geoff Hall. It was first listed on the in 1996. Shire's initial products were calcium supplements (Calcichew-D3) for patients seeking to treat or prevent osteoporosis. In 1997 the company acquired Pharmavene for £105 million in order to access Pharmavene's drug delivery methods. Later in the same year Shire acquired Richwood Pharmaceutical Company, forming Shire-Richwood Inc.
In 2001 the company acquired Biochem Canada. Shire's next acquisition didn't come until 2005 when it acquired Transkaryotic Therapeutics and two years later - in 2007 - New River Pharmaceuticals Inc, for a then company record of $2.6 billion. With the purchase of New River, Shire gained access and ownership of Vyvanse. A year late the company acquired the German company Jerini, for $521 million. Jerini focused on treating hereditary angioedema.
...
Wikipedia